Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/34196 |
Resumo: | Ministry of Heath UNODC (agreement 113/2013) for financial support. We also thank Coordenac¸ão de Aperfeiçoamento de Pessoal de Nível Superior (finance code: 001) for supporting Fernanda Demitto as a post graduate student and the help from Ivan Maia and Betaˆnia Nogueira in collecting information for the dataset. The work from BBA was supported by intramural research program from FIOCRUZ and from the National Institutes of Health (U01AI115940). MBA received a fellowship from the Fundac¸ão de Amparo à Pesquisa da Bahia (FAPESB). |
id |
CRUZ_29958105c2d84ddefe4fc4c22a90cc8d |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/34196 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Demitto, Fernanda de OliveiraSchmaltz, Carolina Arana StanisSant’Anna, Flávia M.Arriaga Gutiérrez, María BelenAndrade, Bruno de BezerrilRolla, Valeria Cavalcanti2019-07-17T17:12:08Z2019-07-17T17:12:08Z2019DEMITTO, Fernanda de Oliveira et al. Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil. Plos One, v. 14, n. 6, p. 1-11, June 2019.1932-6203https://www.arca.fiocruz.br/handle/icict/3419610.1371/journal.pone.0217014Ministry of Heath UNODC (agreement 113/2013) for financial support. We also thank Coordenac¸ão de Aperfeiçoamento de Pessoal de Nível Superior (finance code: 001) for supporting Fernanda Demitto as a post graduate student and the help from Ivan Maia and Betaˆnia Nogueira in collecting information for the dataset. The work from BBA was supported by intramural research program from FIOCRUZ and from the National Institutes of Health (U01AI115940). MBA received a fellowship from the Fundac¸ão de Amparo à Pesquisa da Bahia (FAPESB).Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Pos-Graduação em Pesquisa Clınica em Doenças Infecciosas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.Multinational Organization Network Sponsoring Translational and Epidemiological Research. Initiative, Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz, Salvador, BA, Brasil.Multinational Organization Network Sponsoring Translational and Epidemiological Research. Initiative, Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz, Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Pós-Graduação em Pesquisa Clínica em Doenças Infecciosas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.Background: The implementation of antiretroviral (ARV) therapy caused a significant decrease in HIVassociated mortality worldwide. Nevertheless, mortality is still high among people living with HIV/AIDS and tuberculosis (TB). ARV-naïve HIV patients coinfected with tuberculosis (TB) have more options to treat both diseases concomitantly. Nevertheless, some TB-HIV patients undertaking ARVs (ARV-experienced) are already failing the first line efavirenzbased regimen and seem to display different response to second line ARV therapy and exhibit other predictors of mortality. Methods: We performed a retrospective cohort study including 273 patients diagnosed with TB-HIV and treated at a referral center in Rio de Janeiro, Brazil, between 2008 and 2016. Multivariate analysis and Cox regression models were used to evaluate the effectiveness of ARV therapy regimens (viral load [VL] <80 copies from the 4th to 10th months after TB therapy introduction) and to identify predictors of early mortality (100 days after TB therapy initiation) considering ARV-naïve and ARV-experienced patients adjusting for sociodemographic, clinical and therapeutic covariates. Findings: Survival analysis included 273 patients, out of whom 154 (56.4%) were ARV-naïve and 119 (43.6%) were ARV-experienced. Seven deaths occurred within 6 months of anti-TB treatment, 4 in ARV-naïve and 3 in ARV-experienced patients. Multivariate analysis revealed that in ARV-naïve patients, the chance of death was substantially higher in patients who developed immune reconstitution inflammatory syndrome during the study follow up (HR = 40.6, p<0.01). For ARV-experienced patients, similar analyses failed to identify factors significantly associated with mortality. Variables independently associated with treatment failure for the ARV-naïve group were previous TB (adjusted OR [aOR] = 6.1 p = 0.03) and alcohol abuse (aOR = 3.7 p = 0.01). For ARV-experienced patients, a ritonavir boosted. Protease Inhibitor-based regimen resulted in a 2.6 times higher risk of treatment failure compared to the use of efavirenz based ARV regimens (p = 0.03) and High baseline HIV VL (p = 0.03) were predictors of treatment failure. Conclusions: Risk factors for mortality and ARV failure were different for ARV-naïve and ARV-experienced patients. The latter patient group should be targeted for trials with less toxic and rifampicin-compatible drugs to improve TB-HIV treatment outcomes and prevent death.engPublic Library of ScienceHIVMortalidadeFatores de riscoTratamentoHumanosBrasilHIVMortalityRisk factorsTreatmentHumansBrazilPredictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/34196/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALDemitto, F.O. Predictors of early...2019.pdfDemitto, F.O. Predictors of early...2019.pdfapplication/pdf520233https://www.arca.fiocruz.br/bitstream/icict/34196/2/Demitto%2c%20F.O.%20Predictors%20of%20early...2019.pdf36374fb159b5119e4bff5e0f1311a129MD52TEXTDemitto, F.O. Predictors of early...2019.pdf.txtDemitto, F.O. Predictors of early...2019.pdf.txtExtracted texttext/plain39809https://www.arca.fiocruz.br/bitstream/icict/34196/3/Demitto%2c%20F.O.%20Predictors%20of%20early...2019.pdf.txt880b95e3fe14213a964426d6d7a50901MD53icict/341962023-03-15 14:33:54.468oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:33:54Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil |
title |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil |
spellingShingle |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil Demitto, Fernanda de Oliveira HIV Mortalidade Fatores de risco Tratamento Humanos Brasil HIV Mortality Risk factors Treatment Humans Brazil |
title_short |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil |
title_full |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil |
title_fullStr |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil |
title_full_unstemmed |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil |
title_sort |
Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil |
author |
Demitto, Fernanda de Oliveira |
author_facet |
Demitto, Fernanda de Oliveira Schmaltz, Carolina Arana Stanis Sant’Anna, Flávia M. Arriaga Gutiérrez, María Belen Andrade, Bruno de Bezerril Rolla, Valeria Cavalcanti |
author_role |
author |
author2 |
Schmaltz, Carolina Arana Stanis Sant’Anna, Flávia M. Arriaga Gutiérrez, María Belen Andrade, Bruno de Bezerril Rolla, Valeria Cavalcanti |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Demitto, Fernanda de Oliveira Schmaltz, Carolina Arana Stanis Sant’Anna, Flávia M. Arriaga Gutiérrez, María Belen Andrade, Bruno de Bezerril Rolla, Valeria Cavalcanti |
dc.subject.other.pt_BR.fl_str_mv |
HIV Mortalidade Fatores de risco Tratamento Humanos Brasil |
topic |
HIV Mortalidade Fatores de risco Tratamento Humanos Brasil HIV Mortality Risk factors Treatment Humans Brazil |
dc.subject.en.pt_BR.fl_str_mv |
HIV Mortality Risk factors Treatment Humans Brazil |
description |
Ministry of Heath UNODC (agreement 113/2013) for financial support. We also thank Coordenac¸ão de Aperfeiçoamento de Pessoal de Nível Superior (finance code: 001) for supporting Fernanda Demitto as a post graduate student and the help from Ivan Maia and Betaˆnia Nogueira in collecting information for the dataset. The work from BBA was supported by intramural research program from FIOCRUZ and from the National Institutes of Health (U01AI115940). MBA received a fellowship from the Fundac¸ão de Amparo à Pesquisa da Bahia (FAPESB). |
publishDate |
2019 |
dc.date.accessioned.fl_str_mv |
2019-07-17T17:12:08Z |
dc.date.available.fl_str_mv |
2019-07-17T17:12:08Z |
dc.date.issued.fl_str_mv |
2019 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
DEMITTO, Fernanda de Oliveira et al. Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil. Plos One, v. 14, n. 6, p. 1-11, June 2019. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/34196 |
dc.identifier.issn.pt_BR.fl_str_mv |
1932-6203 |
dc.identifier.doi.pt_BR.fl_str_mv |
10.1371/journal.pone.0217014 |
identifier_str_mv |
DEMITTO, Fernanda de Oliveira et al. Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil. Plos One, v. 14, n. 6, p. 1-11, June 2019. 1932-6203 10.1371/journal.pone.0217014 |
url |
https://www.arca.fiocruz.br/handle/icict/34196 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Public Library of Science |
publisher.none.fl_str_mv |
Public Library of Science |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/34196/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/34196/2/Demitto%2c%20F.O.%20Predictors%20of%20early...2019.pdf https://www.arca.fiocruz.br/bitstream/icict/34196/3/Demitto%2c%20F.O.%20Predictors%20of%20early...2019.pdf.txt |
bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 36374fb159b5119e4bff5e0f1311a129 880b95e3fe14213a964426d6d7a50901 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813009271600709632 |